Mindfulness-Based Cognitive Therapy for Cancer: Gently Turning Towards

 Oncology  Comments Off on Mindfulness-Based Cognitive Therapy for Cancer: Gently Turning Towards
Feb 052019
 

Mindfulness-based Cognitive Therapy for Cancer presents an eight-week course for MBCT which has been tried and tested over ten years of clinical use, and is targeted specifically for people with cancer. There is growing evidence of mindfulness as a successful and cost-effective intervention for reducing the negative psychological impact of cancer and treatment  Content: Chapter One Mindfulness and Cancer (pages 11–22): Chapter Two Cancer – The Psychological Implications (pages 23–32): Stirling Moorey and Ursula BatesChapter Three Cancer – The Medical Implications (pages 33–42): Nicholas S. A. StuartChapter Four The First Circle – Cancer and the Circle of Suffering (pages 43–47): Chapter Five Starting out (pages 55–66): Chapter Six The Eight Week Course (pages 72–242): Chapter Seven The Second Circle: Mindful Awareness and the Circle of Practice (pages 243–249): Chapter Eight The Practices (pages 254–283): Chapter Nine Mindfulness in Palliative Care (pages 289–302): Ursula BatesChapter Ten After the Eight Week Course (pages 303–309): Chapter Eleven The Third Circle – Being and the Circle of Presence (pages 310–317): Chapter Twelve Introducing the Teacher (pages 321–327): Chapter 13 Embodying The Practice (pages 328–339): Chapter Fourteen Facilitating the Learning (pages 340–353): Chapter Fifteen The Three Circle Model: A Formulation of MBCT for Cancer (MBCT?Ca) (pages 354–363): Trish Bartley and Ursula Bates
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development

 Oncology  Comments Off on Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
Feb 042019
 

Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.Content: Chapter 1 Introduction (pages 1–5): George C. PrendergastChapter 2 Molecular Cancer Therapeutics: Will the Promise be Fulfilled? (pages 7–40): Beverly A. TeicherChapter 3 Cancer Genetics and Drug Target Selection (pages 41–53): Guo?Jun Zhang and William G. KaelinChapter 4 RNA Interference in Mammals: Journey to the Center of Human Disease (pages 55–72): Patrick J. Paddison and Gregory J. HannonChapter 5 Applications and Issues for Tissue Arrays in Target and Drug Discovery (pages 73–90): Eric Jonasch, Kim?Anh Do, Christopher Logothetis and Timothy J. McDonnellChapter 6 Protein Transduction Strategies for Target and Mechanism Validation (pages 91–118): Sergei A. Ezhevsky and Steven F. DowdyChapter 7 Drug Screening: Assay Development Issues (pages 119–140): Steven S. Carroll, James Inglese, Shi?Shan Mao and David B. OlsenChapter 8 Gene Microarray Technologies for Cancer Drug Discovery and Development (pages 141–186): Robert H. te Poele, Paul A. Clarke and Paul WorkmanChapter 9 Transgenic Mouse Models of Cancer (pages 187–202): T. J. Bowen and A. Wynshaw?BorisChapter 10 Transgenic Versus Xenograft Mouse Models of Cancer: Utility and Issues (pages 203–226): Ming Liu, W. Robert Bishop, Yaolin Wang and Paul KirschmeierChapter 11 Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring (pages 227–254): Robert B. Lobell, Nancy E. Kohl and Laura Sepp?LorenzinoChapter 12 Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development (pages 255–286): Pamela A. Benfield and Bruce D. CarChapter 13 Clinical Development Issues (pages 287–306): Steven D. Averbuch, Michael K. Wolf, Basil F. El?Rayes and Patricia M. LoRussoChapter 14 Intellectual Property and Commercialization Issues in Drug Discovery (pages 307–327): Lisa Gail Malseed
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

Targeting Notch in Cancer: From the Fruit Fly to the Clinic

 Oncology  Comments Off on Targeting Notch in Cancer: From the Fruit Fly to the Clinic
Feb 012019
 


The serendipitously discovered link between developmental biology and cancer, touched of an explosion of discoveries on the role of Notch in human malignancies, including every aspect of cancer biology, from control of differentiation, proliferation and apoptosis in transformed cells to angiogenesis, tumor-stroma interaction and anti-cancer immune responses. A number of observations have revealed that Notch even plays a role in the renewal of cancer stem cells and tumor initiating cells, which are thought to be a major cause of resistance to treatment. Targeting Notch in Cancer will provide researchers, oncologists, pharmacologists and students with a detailed understanding of the intricate cross-talk between Notch and other pathways of therapeutic interest so to better design rational drug combinations for specific diseases and disease subsets.

Divided into two parts, Part I describes in detail what we know about the genetics, molecular biology, biochemistry and structural biology of Notch, as well as the role of Notch in such processes as angiogenesis and immune surveillance. Without insights gained from these basic studies, rational targeting of Notch in human disease would be impossible. Part II describes the role of Notch and ongoing experimental therapeutic efforts in the most important subtypes of human cancers, organized in a clinically oriented fashion by organs and systems affected.

GET IT FREE HERE

http://nitroflare.com/view/33623B60F1D35F1/1493988573.pdf

ALTERNATIVE LINK

https://filejoker.net/nkvvcjxchdjn

Share Button

Uterine Cervical Cancer: Clinical and Therapeutic Perspectives

 Oncology  Comments Off on Uterine Cervical Cancer: Clinical and Therapeutic Perspectives
Feb 012019
 

This volume provides a broad background of the basic sciences, clinical and therapeutic aspects, and management of uterine cervical cancer. It offers state-of-the-art information on the molecular genetics, biology, and clinical aspects of premalignant lesions of the uterine cervix, and provides a better understanding of the molecular and cellular events that underlie uterine cervical cancer. Uterine Cervical Cancer: Clinical and Therapeutic Perspectives contains extensive, updated information on the promising new developments in the diagnosis and management of uterine cervical cancer. It will serve as an invaluable resource for all clinicians and basic medical scientists caring for women with uterine cervical cancer, including attending surgeons, physicians, clinical fellows, and residents in the disciplines of gynecologic oncology, medical oncology, and surgical oncology.
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

Taxane Anticancer Agents. Basic Science and Current Status

 Oncology  Comments Off on Taxane Anticancer Agents. Basic Science and Current Status
Jan 312019
 

Presents an overview of the development of paclitaxel as an anticancer drug, including the discovery, initial development, current status, supply issues, and recent clinical developments. Discusses in detail the cellular mechanism of action and the toxicity of paclitaxel. Presents drug delivery and taxotere metabolism. Explains semisynthetic and medicinal chemistry studies. Covers approaches to the total synthesis of paclitaxel.
Content: Overview of paclitaxel research : progress on many fronts / Matthew Suffness — Paclitaxel : from discovery to clinic / Monroe E. Wall and Mansukh C. Wani — Current status of clinical trials with paclitaxel and docetaxel / F.A. Holmes, A.P. Kudelka, J.J. Kavanagh, M.H. Huber, J.A. Ajani, and V. Valero — The Pacific yew environmental impact statement / S.J. Campbell and S.A. Whitney — Paclitaxel biosynthesis : the early steps / Rodney Croteau, Mehri Hezari, Jerry Hefner, Alfred Koepp, and Norman G. Lewis — Bioactive metabolites of the endophytic fungi of Pacific yew, Taxus brevifolia : paclitaxel, taxanes, and other bioactive compounds / Andrea Stierle, Donald Stierle, Gary Strobel, Gary Bignami, and Paul Grothaus — Metabolism of taxoid drugs / M. Vuilhorgne, C. Gaillard, G.J. Sanderink, I. Royer, B. Monsarrat, J. Dubois, and M. Wright — Pharmacology and antitumor effect of novel paclitaxel formulations / R.M. Straubinger, A. Sharma, U.S. Sharma, and S.V. Balasubramanian — Phosphatase-activated prodrugs of paclitaxel / D.M. Vyas, Y. Ueda, H. Wong, J.D. Matiskella, S. Hauck, A.B. Mikkilineni, Vittorio Farina, W.C. Rose, and A.M. Casazza — Microtubule polymerization dynamics, mitotic block, and cell death by paclitaxel at low concentrations / Mary Ann Jordon and Leslie Wilson — Photoincorporation of a paclitaxel photoaffinity analogue into the N-terminal 31 amino acids of [beta]-tubulin / Susan Band Horwitz, Srinivasa Rao, Nancy E. Krauss, Julie M. Heerding, Charles S. Swindell, Israel Ringel, and George A. Orr — Paclitaxel, a mimetic of bacterial lipopolysaccharide (LPS) in murine macrophages / S.N. Vogel, J.M. Carboni, and C.L. Manthey — The roles of the cytoskeleton in steroidogenesis : the actions of paclitaxel and other cytoskeletal agents / Pamela J. Massey, Michael R. Caudle, Jeffrey K. Keenan, and Thomas T. Chen — Chemistry and structure-activity relationships of taxoids with modified skeletons / F. Guéritte-Voegelein, D. Guénard, J. Dubois, A. Wahl, R. Marder, R. Müller, M. Lund, L. Bricard, and P. Potier — Recent advances in the chemistry and structure-activity relationships of paclitaxel / David G.I. Kingston — Medicinal chemistry of paclitaxel : chemistry, structure-activity relationships, and conformational analysis / Gunda I. Georg, Geraldine C.B. Harriman, David G. Vander Velde, Thomas C. Boge, Zacharia S. Cheruvallath, Apurba Datta, Michael Hepperle, Haeil Park, Richard H. Himes, and Lalith Jayasinghe — Practical semisynthesis and antimitotic activity of docetaxel and side-chain analogues / A. Commerçon, J.D. Bourzat, E. Didier, and François Lavelle — Paclitaxel structure-activity relationships and core skeletal rearrangements / Shu-Hui Chen and Vittorio Farina — Syntheses and structure-activity relationships of new taxoids / Iwao Ojima, Young Hoon Park, Ivana Fenoglio, Olivier Duclos, Chung-Ming Sun, Scott D. Kuduk, Martine Zucco, Giovanni Appendino, Paula Pera, Jean M. Veith, Ralph J. Bernacki, Marie-Christine Bissery, C. Combeau, P. Vrignaud, J.F. Riou, and François Lavelle — Chemistry and antitumor activity of 9(R)-dihydrotaxanes / L.L. Klein, L. Li, C.M. Yeung, C.J. Maring, S.A. Thomas, D.J. Grampovnik, and J.J. Plattner — The total synthesis of paclitaxel starting with camphor / Robert A. Holton, Carmen Somoza, Hyeong-Baik Kim, Feng Liang, Ronald J. Biediger, P. Douglas Boatman, Mitsuru Shindo, Chase C. Smith, Soekchan Kim, Hossain Nadizadeh, Yukio Suzuki, Chunlin Tao, Phong Vu, Suhan Tang, Pingsheng Zhang, Krishna K. Murthi, Lisa N. Gentile, and Jyanwei H. Liu — The total synthesis of paclitaxel by assembly of the ring system / K.C. Nicolaou and R.K. Guy — Toward the design of a convergent practical route to all classes of taxanes / Leo A. Paquette — The pinene path to taxanes : genesis and evolution of a strategy for synthesis / Paul A. Wender, Neil F. Badham, Simon P. Conway, Paul E. Floreancig, Timothy E. Glass, Jonathan B. Houze, Nancy E. Krauss, Daesung Lee, Daniel G. Marquess, Paul L. McGrane, Wei Meng, Thomas P. Mucciaro, Michel Mühlebach, Michael G. Natchus, Takeshi Ohkuma, Bernd Peschke, David B. Rawlins, Anthony J. Shuker, Jim C. Sutton, Richard E. Taylor, Katsuhiko Tomooka, and Ludger A. Wessjohann.
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

Colorectal Cancer in Clinical Practice: Prevention, Early Detection and Management, Second Edition

 Oncology  Comments Off on Colorectal Cancer in Clinical Practice: Prevention, Early Detection and Management, Second Edition
Jan 272019
 

The rapid rate of development in the fields of prevention, early detection and management for colorectal cancer means that the successful first edition of this accessible guide has needed to be updated and revised throughout. Primary care physicians and specialists alike will continue to find this an indispensable synopsis of the issues and options.
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

100 Q&as About Uterine Cancer

 Oncology  Comments Off on 100 Q&as About Uterine Cancer
Jan 252019
 

Whether you are a newly diagnosed uterine cancer patient, a survivor, or a friend or relative of either, this book offers help. 100 Questions and Answers About Uterine Cancer addresses the issues that are specific to the woman with uterine cancer. Written by two renowned gynecologic oncologists and including insider advice from an actual patient, this book gives you authoritative, practical answers to your questions about uterine cancer.

GET IT FREE HERE

http://nitroflare.com/view/4A103F0B91B1088/0763776580.PDF

ALTERNATIVE LINK

https://filejoker.net/s9qf2fdtriyy

Share Button

Small Molecules in Oncology (2nd edition)

 Oncology  Comments Off on Small Molecules in Oncology (2nd edition)
Jan 242019
 

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance: From Basic to Clinical Research

 Neurology/Neurosurgery, Oncology  Comments Off on Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance: From Basic to Clinical Research
Jan 212019
 

The book describes the ability of a series of endocrine-derived compounds, i.e. CHRH, LHRH, somatostatin, anti-androgens, and aromatase inhibitors to exert a direct anti-neoplastic activity or to potentiate the activity of traditional chemotherapeutic agents on neuroendocrine and solid tumors. In addition, a new class of potent GH-releasers, GSHs/Ghrelin, endowed with important endocrine and extra-endcocrine action, is presented. Therefore, in addition to traditional chemotherapy, characterized by high toxicity and non-selective action on tumoral cells, the reader can find a new approach with more selective, less cytotoxic endocrine derived compounds
GET IT FREE HERE
ALTERNATIVE LINK
Share Button

Early Diagnosis in Neuro-oncology

 Neurology/Neurosurgery, Oncology  Comments Off on Early Diagnosis in Neuro-oncology
Jan 192019
 

It is common knowledge that a clinical diagnosis is based on a combination of symptoms and signs, observed in their evolution. Advancing the diagnosis at an early stage and particularly in the neurosurgical clinical examination would enhance the slightest possibility of recovery, theoretically almost transforming it into a concrete possibility. This book has a precise goal: to examine the “germ” of diagnostic suspicion, which is the true salt of medical art for every physician, general practitioner and specialist alike. In some cases also the characteristics of the late clinical picture are presented: today, though, this must be considered as a medical failure.
GET IT FREE HERE
ALTERNATIVE LINK
Share Button